Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RAD51C |
Variant | E45D |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | RAD51C E45D lies within a region of the Rad51c protein required for Holliday junction resolution activity (UniProt.org). E45D has been identified in sequencing studies (PMID: 24185509), but has not been biochemically characterized and therefore, its effect on Rad51c protein function is unknown (PubMed, Oct 2024). |
Associated Drug Resistance | |
Category Variants Paths |
RAD51C mutant RAD51C E45D |
Transcript | NM_058216.3 |
gDNA | chr17:g.58692778G>C |
cDNA | c.135G>C |
Protein | p.E45D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002876.4 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
NM_058216 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722001 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
NM_002876.3 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722001.5 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
NM_058216.2 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
NM_002876 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722002.5 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722002 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
NM_058216.3 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722002.4 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_047436505.1 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
XM_006722001.4 | chr17:g.58692778G>C | c.135G>C | p.E45D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51C mutant | ovarian cancer | not applicable | N/A | Guideline | Risk Factor | Germline RAD51C mutations are associated with increased risk of developing ovarian cancer (NCCN.org). | detail... |
RAD51C mutant | ovarian serous carcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in a complete response with treatment ongoing at 14 months in a patient with relapsed, metastatic high grade serous ovarian carcinoma harboring RAD51C mutations (PMID: 36176748). | 36176748 |
RAD51C mutant | breast cancer | not applicable | N/A | Guideline | Risk Factor | Germline RAD51C mutations are associated with increased risk of developing breast cancer (NCCN.org). | detail... |